CDH1 and ovarian carcinoma: Evidence indicates that the loss of E-cadherin is associated with ovarian cancer metastasis, peritoneal dissemination and poor patient survival [22]–[26], suggesting that E-cadherin functions as a suppressor of tumor invasiveness.